- Home
- FFIV vs GMAB Comparison
FFIV vs GMAB Comparison
Compare FFIV & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIV
- GMAB
- Stock Information
- Founded
- FFIV 1996
- GMAB 1999
- Country
- FFIV United States
- GMAB Denmark
- Employees
- FFIV N/A
- GMAB N/A
- Industry
- FFIV Computer Communications Equipment
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FFIV Telecommunications
- GMAB Health Care
- Exchange
- FFIV Nasdaq
- GMAB Nasdaq
- Market Cap
- FFIV 16.7B
- GMAB 17.4B
- IPO Year
- FFIV 1999
- GMAB N/A
- Fundamental
- Price
- FFIV $241.10
- GMAB $30.51
- Analyst Decision
- FFIV Hold
- GMAB Strong Buy
- Analyst Count
- FFIV 11
- GMAB 6
- Target Price
- FFIV $297.22
- GMAB $40.40
- AVG Volume (30 Days)
- FFIV 1.3M
- GMAB 2.6M
- Earning Date
- FFIV 10-27-2025
- GMAB 11-06-2025
- Dividend Yield
- FFIV N/A
- GMAB N/A
- EPS Growth
- FFIV 23.56
- GMAB 132.41
- EPS
- FFIV 11.80
- GMAB 25.10
- Revenue
- FFIV $3,088,072,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- FFIV $4.08
- GMAB $24.92
- Revenue Next Year
- FFIV $3.95
- GMAB $15.97
- P/E Ratio
- FFIV $20.21
- GMAB $1.21
- Revenue Growth
- FFIV 9.66
- GMAB 29.57
- 52 Week Low
- FFIV $227.05
- GMAB $17.24
- 52 Week High
- FFIV $346.00
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- FFIV 23.59
- GMAB 57.92
- Support Level
- FFIV $237.54
- GMAB $28.08
- Resistance Level
- FFIV $248.61
- GMAB $29.35
- Average True Range (ATR)
- FFIV 7.69
- GMAB 0.69
- MACD
- FFIV -1.81
- GMAB 0.02
- Stochastic Oscillator
- FFIV 3.82
- GMAB 93.60
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.